These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 39244136)
1. A review of chitosan polysaccharides: Neuropharmacological implications and tissue regeneration. Ait Hamdan Y; El-Mansoury B; Elouali S; Rachmoune K; Belbachir A; Oudadesse H; Rhazi M Int J Biol Macromol; 2024 Nov; 279(Pt 3):135356. PubMed ID: 39244136 [TBL] [Abstract][Full Text] [Related]
2. Are extracellular vesicles new hope in clinical drug delivery for neurological disorders? Muhammad SA Neurochem Int; 2021 Mar; 144():104955. PubMed ID: 33412233 [TBL] [Abstract][Full Text] [Related]
3. Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review. Krsek A; Jagodic A; Baticic L Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336425 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of fucoidan in central nervous system disorders: A systematic review. Yang J; Zhao H; Qu S Int J Biol Macromol; 2024 Oct; 277(Pt 3):134397. PubMed ID: 39097066 [TBL] [Abstract][Full Text] [Related]
5. Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases. Mansor NI; Nordin N; Mohamed F; Ling KH; Rosli R; Hassan Z Curr Drug Deliv; 2019; 16(8):698-711. PubMed ID: 31456519 [TBL] [Abstract][Full Text] [Related]
6. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair. Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949 [TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery: circumventing the iron curtain to treat neurological disorders. Jiang Y; Li Y; Liu X Expert Opin Drug Deliv; 2015; 12(11):1717-25. PubMed ID: 26206202 [TBL] [Abstract][Full Text] [Related]
8. Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders. Kumar S; Singh P; Sharma S; Pottoo FH; Ali J; Baboota S Comb Chem High Throughput Screen; 2021; 24(10):1544-1556. PubMed ID: 33334281 [TBL] [Abstract][Full Text] [Related]
9. A review of chitosan-based nanocarriers as drug delivery systems for brain diseases: Critical challenges, outlooks and promises. Khodaverdi K; Bakhshi A; Mozafari MR; Naghib SM Int J Biol Macromol; 2024 Oct; 278(Pt 3):134962. PubMed ID: 39179064 [TBL] [Abstract][Full Text] [Related]
10. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies. Zhao X; Ye Y; Ge S; Sun P; Yu P Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962 [TBL] [Abstract][Full Text] [Related]
11. Recent progress of drug nanoformulations targeting to brain. Khan AR; Yang X; Fu M; Zhai G J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256 [TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders. Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274 [TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders. Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530 [TBL] [Abstract][Full Text] [Related]
14. Enabling biodegradable functional biomaterials for the management of neurological disorders. Shan D; Ma C; Yang J Adv Drug Deliv Rev; 2019 Aug; 148():219-238. PubMed ID: 31228483 [TBL] [Abstract][Full Text] [Related]
15. Applications of chitin and chitosan nanofibers in bone regenerative engineering. Tao F; Cheng Y; Shi X; Zheng H; Du Y; Xiang W; Deng H Carbohydr Polym; 2020 Feb; 230():115658. PubMed ID: 31887899 [TBL] [Abstract][Full Text] [Related]
16. The protective effects of natural products on blood-brain barrier breakdown. Kam A; Li KM; Razmovski-Naumovski V; Nammi S; Chan K; Li Y; Li GQ Curr Med Chem; 2012; 19(12):1830-45. PubMed ID: 22376038 [TBL] [Abstract][Full Text] [Related]
17. Sulfated Polysaccharide-Based Nanocarrier Drives Microenvironment-Mediated Cerebral Neurovascular Remodeling for Ischemic Stroke Treatment. Cao Y; Yu Y; Pan L; Han W; Zeng F; Wang J; Mei Q; Liu C Nano Lett; 2024 May; 24(17):5214-5223. PubMed ID: 38649327 [TBL] [Abstract][Full Text] [Related]
18. Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System. Ojeda-Hernández DD; Canales-Aguirre AA; Matias-Guiu J; Gomez-Pinedo U; Mateos-Díaz JC Front Bioeng Biotechnol; 2020; 8():389. PubMed ID: 32432095 [TBL] [Abstract][Full Text] [Related]
19. A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders. Shayganfard M Curr Pharm Biotechnol; 2022; 23(4):538-551. PubMed ID: 34161209 [TBL] [Abstract][Full Text] [Related]
20. Amino acid transporters in neurological disorders and neuroprotective effects of cysteine derivatives. Adla SK; Virtanen H; Thongsodsaeng T; Huttunen KM Neurochem Int; 2024 Jul; 177():105771. PubMed ID: 38761853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]